Different combinations of cytokines and activating receptor stimuli are required for human natural killer cell functional diversity

Cytokine

Volumn 62, Issue 1, 2013, Pages 58-63

  Varchetta, Stefania ^a   Oliviero, Barbara ^a   Mavilio, Domenico ^b   Mondelli, Mario U ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

CD107a; Interferon gamma; Interleukin 21; Natural killer cell receptors; Tumor necrosis factor alfa

Indexed keywords

CD16 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; CYTOLYSIS; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANTIGENS, CD56; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-2; INTERLEUKINS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; RECEPTORS, IGG; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875803691     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.02.018     Document Type: Article

References (31)

1. Colucci F., Caligiuri M.A., Di Santo J.P. What does it take to make a natural killer?. Nat Rev Immunol 2003, 3:413-425.
2. Becknell B., Caligiuri M.A. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 2005, 86:209-239.
3. Skak K., Frederiksen K.S., Lundsgaard D. Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology 2007.
4. Parrish-Novak J., Dillon S.R., Nelson A., Hammond A., Sprecher C., Gross J.A., et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000, 408:57-63.
5. Roda J.M., Parihar R., Lehman A., Mani A., Tridandapani S., Carson W.E. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol 2006, 177:120-129.
6. Strengell M., Matikainen S., Siren J., Lehtonen A., Foster D., Julkunen I., et al. IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J Immunol 2003, 170:5464-5469.
7. Kishida T., Asada H., Itokawa Y., Cui F.D., Shin-Ya M., Gojo S., et al. Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma. Mol Ther 2003, 8:552-558.
8. Nakano H., Kishida T., Asada H., Shin-Ya M., Shinomiya T., Imanishi J., et al. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma. J Gene Med 2006, 8:90-99.
9. de Rham C., Ferrari-Lacraz S., Jendly S., Schneiter G., Dayer J.M., Villard J. The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors. Arthritis Res Ther 2007, 9:R125.
10. Sondergaard H., Frederiksen K.S., Thygesen P., Galsgaard E.D., Skak K., Kristjansen P.E., et al. Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors. Cancer Immunol Immunother 2007, 56:1417-1428.
11. Brady J., Hayakawa Y., Smyth M.J., Nutt S.L. IL-21 induces the functional maturation of murine NK cells. J Immunol 2004, 172:2048-2058.
12. Di Carlo E., Comes A., Orengo A.M., Rosso O., Meazza R., Musiani P., et al. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. J Immunol 2004, 172:1540-1547.
13. Moroz A., Eppolito C., Li Q., Tao J., Clegg C.H., Shrikant P.A. IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol 2004, 173:900-909.
14. Moretta A., Bottino C., Vitale M., Pende D., Cantoni C., Mingari M.C., et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001, 19:197-223.
15. Trinchieri G., Valiante N. Receptors for the Fc fragment of IgG on natural killer cells. Nat Immunol 1993, 12:218-234.
16. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6:443-446.
17. Skak K., Frederiksen K.S., Lundsgaard D. Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology 2008, 123:575-583.
18. Wendt K., Wilk E., Buyny S., Schmidt RE., Jacobs R. Interleukin-21 differentially affects human natural killer cell subsets. Immunology 2007.
19. Park Y.K., Shin D.J., Cho D., Kim S.K., Lee J.J., Shin M.G., et al. Interleukin-21 increases direct cytotoxicity and IFN-gamma production of ex vivo expanded NK cells towards breast cancer cells. Anticancer Res 2012, 32:839-846.
20. Newman K.C., Riley E.M. Whatever turns you on: accessory-cell-dependent activation of NK cells by pathogens. Nat Rev Immunol 2007, 7:279-291.
21. Colucci F., Rosmaraki E., Bregenholt S., Samson S.I., Di Bartolo V., Turner M., et al. Functional dichotomy in natural killer cell signaling: Vav1-dependent and -independent mechanisms. J Exp Med 2001, 193:1413-1424.
22. Huntington N.D., Xu Y., Nutt S.L., Tarlinton D.M. A requirement for CD45 distinguishes Ly49D-mediated cytokine and chemokine production from killing in primary natural killer cells. J Exp Med 2005, 201:1421-1433.
23. Hesslein D.G., Takaki R., Hermiston M.L., Weiss A., Lanier L.L. Dysregulation of signaling pathways in CD45-deficient NK cells leads to differentially regulated cytotoxicity and cytokine production. Proc Natl Acad Sci USA 2006, 103:7012-7017.
24. Mason L.H., Willette-Brown J., Taylor L.S., McVicar D.W. Regulation of Ly49D/DAP12 signal transduction by Src-family kinases and CD45. J Immunol 2006, 176:6615-6623.
25. Zompi S., Hamerman J.A., Ogasawara K., Schweighoffer E., Tybulewicz V.L., Di Santo J.P., et al. NKG2D triggers cytotoxicity in mouse NK cells lacking DAP12 or Syk family kinases. Nat Immunol 2003, 4:565-572.
26. Kim N., Saudemont A., Webb L., Camps M., Ruckle T., Hirsch E., et al. The p110delta catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion. Blood 2007, 110:3202-3208.
27. Malarkannan S., Regunathan J., Chu H., Kutlesa S., Chen Y., Zeng H., et al. Bcl10 plays a divergent role in NK cell-mediated cytotoxicity and cytokine generation. J Immunol 2007, 179:3752-3762.
28. Ussat S., Scherer G., Fazio J., Beetz S., Kabelitz D., Adam-Klages S. Human NK cells require caspases for activation-induced proliferation and cytokine release but not for cytotoxicity. Scand J Immunol 2010, 72:388-395.
29. De Maria A., Bozzano F., Cantoni C., Moretta L. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim) CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci USA 2011, 108:728-732.
30. Beziat V., Duffy D., Quoc S.N., Le Garff-Tavernier M., Decocq J., Combadiere B., et al. CD56brightCD16+ NK cells: a functional intermediate stage of NK cell differentiation. J Immunol 2011, 186:6753-6761.
31. Burgess S.J., Marusina A.I., Pathmanathan I., Borrego F., Coligan J.E. IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells. J Immunol 2006, 176:1490-1497.